Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The HOPE Study: Characterizing Patients With Hepatitis B and C
NCT02995252 · View on ClinicalTrials.gov ↗
Study Summary
This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and evaluation of disease progression. In addition, there is a longitudinal sub-study for treatment of hepatitis B that will involve 2 years of treatment with tenofovir alafenamide and blood collections with optional liver biopsies.
Conditions Studied
Interventions
- PROCEDURE Liver Biopsy
- OTHER Blood draws
- DRUG Tenofovir Alafenamide
- OTHER Knowledge Index Questionnaire
- OTHER Liver transient elastography (FibroScan)
Study Locations (2)
Maryland
- Institute of Human Virology, University of Maryland School of Medicine — Baltimore
Virginia
- Dr Huong Dang, Medical Practice — Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2014-12 |
| Est. Completion | 2034-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02995252
The ClinicalTrials.gov registry entry for NCT02995252 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 559 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 5 interventions — of which Liver Biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02995252 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Maryland, Virginia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02995252 about?
NCT02995252 is a clinical study titled "The HOPE Study: Characterizing Patients With Hepatitis B and C". This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and ...
What is the current status of trial NCT02995252?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2014-12. Estimated completion is 2034-12.
What conditions does trial NCT02995252 study?
This clinical trial studies the following conditions: Hepatitis C, Hepatitis B, Chronic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02995252?
The interventions under investigation include: Liver Biopsy (PROCEDURE), Blood draws (OTHER), Tenofovir Alafenamide (DRUG), Knowledge Index Questionnaire (OTHER), Liver transient elastography (FibroScan) (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02995252?
This trial is sponsored by University of Maryland, Baltimore, which has 559 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02995252 being conducted?
This trial has 2 study locations across Maryland, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.